Current Vascular Pharmacology
Title:Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?
Volume: 14 Issue: 1
Author(s): Niki Katsiki, Georgios A. Christou and Dimitrios N. Kiortsis
Affiliation:
Export Options
About this article
Cite this article as:
Katsiki Niki, Christou A. Georgios and Kiortsis N. Dimitrios, Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?, Current Vascular Pharmacology 2016; 14 (1) . https://dx.doi.org/10.2174/157016111401151126161741
DOI https://dx.doi.org/10.2174/157016111401151126161741 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From Antidepressant Drugs to Beta-Mimetics: Preclinical Insights on Potential New Treatments for Neuropathic Pain
Recent Patents on CNS Drug Discovery (Discontinued) Torsades de Pointes in Patients with Polymyalgia Rheumatica
Current Pharmaceutical Design Fetal Mechanisms That Lead to Later Hypertension
Current Drug Targets Apoptosis: Potential Therapeutic Targets for New Drug Discovery
Current Medicinal Chemistry Nutrigenomics and its Impact on Life Style Associated Metabolic Diseases
Current Genomics Antiaging Therapy: A Novel Target for Antilipolytic Drugs
Mini-Reviews in Medicinal Chemistry Susceptibility of Helicobacter pylori to Natural Products: Can Past Research Direct Future Drug Development?
Current Bioactive Compounds Primary and Secondary Insomnia: Prevalence, Causes and Current Therapeutics
Current Medicinal Chemistry - Central Nervous System Agents Clinical Applications for Cardiovascular Magnetic Resonance Imaging at 3 Tesla
Current Cardiology Reviews Aldehyde Dehydrogenase-2 Roles in Ischemic Cardiovascular Disease
Current Drug Targets Diabetes Mellitus in Saudi Arabia: A Review of the Recent Literature
Current Diabetes Reviews Chemistory of Fibrates
Current Chemical Biology Blood Serum Atherogenicity: Cellular Test for the Development of Anti- Atherosclerotic Therapy
Current Pharmaceutical Design Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs
Current Drug Metabolism Somatic Genome Variations in Health and Disease
Current Genomics Synthesis, Physico-Chemical Properties and DFT Calculations of New 2-(4- Arylpiperazine-1-yl)-1-(3-ethylbenzofuran-2-yl)ethanols As Potential Antihypertensive Agents
Current Organic Chemistry Dietary Regulation of Glucose Metabolism in Metabolic Syndrome
Current Vascular Pharmacology Potential Treatment of Cardiac Hypertrophy and Heart Failure by Inhibiting the Sarcolemmal Binding of Phospholipase Cβ1b
Current Drug Targets Myocardial Protection Against Ischemia-Reperfusion Injury: Novel Approaches in Maintaining Homeostatic Stability in Blood
Recent Patents on Cardiovascular Drug Discovery